m+Medelevator.RU
← Поиск публикаций
Frontiers in cell and developmental biology · 2026

Current insights into circulating biomarkers and their potential for predicting adolescent idiopathic scoliosis progression.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Raimondi Lavinia, Colombini Alessandra, Ruffilli Alberto, Perna Fabrizio, Negrini Stefano, Toscano Angelo, Giavaresi Gianluca

Аннотация

Adolescent Idiopathic Scoliosis (AIS) is a three-dimensional deformation of the spine with a frontal plane curvature of 10° or more, measured using Cobb method. It typically gets more severe during pre-puberty and puberty, currently exhibiting unpredictable progression. Severe disease is more prevalent in females, and progression is associated with respiratory and neuromuscular dysfunction, pain, and psychological complications. Management strategies are guided by curve severity and include observation, therapeutic exercises, bracing, and surgery. Despite advances, the cellular and molecular mechanisms driving AIS remain poorly understood. Early detection and reliable progression biomarkers are increasingly recognized as critical to prevent clinical mismanagement. This mini-review summarizes current evidence on circulating biomarkers investigated in AIS, including growth-related hormones, bone metabolism proteins, and more recently non-coding RNAs (ncRNAs) such as microRNAs. In addition, we highlight key methodological limitations and risk-of-bias concerns across existing studies, especially the reliance on single-time-point sampling, underscoring the need for longitudinal prospective cohorts with repeated biomarker measurements. Such designs are critical for capturing dynamic biological changes, distinguishing stable from progressive cases, and validating biomarker trajectories for integration into clinically meaningful prediction models for AIS progression.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты